Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Eosinophilic Esophagitis Clear all

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eosinophilic Esophagitis
Interventions: swallowed sponge device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eosinophilic Esophagitis, Barrett Esophagus
Interventions: SECM capsule; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Gastroenteritis, Dyspepsia
Interventions: montelukast; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Barrett's Esophagus, Eosinophilic Esophagitis
Interventions: OFDI Capsule; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Esophagitis
Interventions: Transnasal esophagoscopy; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 22 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions: Esomeprazole, Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
Interventions: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Eosinophilic Esophagitis
Interventions: Dose; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions: Mepolizumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 6 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions: Dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 36
States / cities: Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more

Conditions: Eosinophilic Gastroenteritis
Interventions: Elemental Diet Therapy; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Year to 65 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Eosinophilic Esophagitis, Food Allergies
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Eosinophilic Esophagitis
Interventions: Budesonide; Drug
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Oral Budesonide Suspension (MB-9), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 11 Years to 40 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • San Diego, California + 17 more

Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions: lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more

Conditions: Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eosinophilic Esophagitis
Interventions: Plasma and urine metabolomics; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: budesonide, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more

Conditions: Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Month to 21 Years
Enrollment: 300 participants
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 0 Years and older
Enrollment: 187 participants
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

Sponge and Eosinophil Peroxidase (EPO) Staining

Imaging of the Esophagus Using a SECM Capsule

Montelukast in the Treatment of Duodenal Eosinophilia

Study to Image the Esophagus Using the OFDI Capsule

CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis

Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)

Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

Metabolomics for Biomarker Discovery in Children With EoE

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population

CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry